Improved detection methods significantly increase the detection window for EPO microdoses
- 31 July 2020
- journal article
- research article
- Published by Wiley in Drug Testing and Analysis
- Vol. 13 (1) , 101-112
Abstract
To reproduce a potential doping scenario, a 2 week administration of recombinant erythropoietin (rEPO) microdoses alone or in combination with growth hormone (GH) microdoses (three times a week) was performed on healthy and athletic male subjects. The aim of this study was to evaluate the identification capability of rEPO in samples obtained during and post treatment. Detection was tested in urine and blood using the antidoping techniques for rEPO detection (iso‐electric focusing (IEF)‐, sodium‐dodecyl‐sulfate (SDS)‐polyacrylamide gel electrophoresis (PAGE) and for some urine samples the sarcosyl (SAR)‐PAGE method) with some improvements: for blood samples, instead of a simple concentration step, immuno‐extraction of EPO was performed for all urines to limit protein contamination that can affect migration. In addition, elution buffer modifications also improved the quality of migration. The use of a recently validated biotinylated anti‐EPO antibody simplified the protocols, allowing a single transfer step instead of a double‐blot even by IEF with a lowered background. The criteria for suspicious blood and urine samples by IEF were also re‐evaluated. While endogenous EPO was not decreased over the course of the study, EPO microdoses were detectable in blood and urine between 24 h and 72 h after an administration. Detection in urine in combination with SDS‐PAGE was the most sensitive combination for prolonged detection (100% identification after 48 h, 91% after 72 h), slightly better than IEF. Urine samples also tested by SAR‐PAGE indicated a similar sensitivity of detection to SDS‐PAGE. GH co‐administration had no impact on rEPO elimination/detection.Keywords
Funding Information
- Agence Française de Lutte contre le Dopage (COS AFLD 2016)
This publication has 25 references indexed in Scilit:
- New insights for identification of doping with recombinant human erythropoietin micro‐doses after high hydrationDrug Testing and Analysis, 2016
- Detection of recombinant EPO in blood and urine samples with EPO WGA MAIIA, IEF and SAR‐PAGE after microdose injectionsDrug Testing and Analysis, 2013
- Effect of single doses of methoxypolyethylene glycol‐epoetin beta (CERA, Mircera™) and epoetin delta (Dynepo™) on isoelectric erythropoietin profiles and haematological parametersDrug Testing and Analysis, 2011
- A fast preparative method for detection of recombinant erythropoietin in blood samplesDrug Testing and Analysis, 2010
- SARCOSYL‐PAGE: a new method for the detection of MIRCERA‐ and EPO‐doping in bloodDrug Testing and Analysis, 2009
- Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping controlHaematologica, 2009
- SDS‐PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping controlDrug Testing and Analysis, 2009
- Detection window of Darbepoetin-α following one single subcutaneous injectionClinica Chimica Acta, 2007
- Recombinant human erythropoietin in sports: a reviewRevista Brasileira de Medicina do Esporte, 2003
- Recombinant erythropoietin in urineNature, 2000